Transcranial magnetic stimulation (TMS) has evolved from a promising research technology into an established treatment option for depression in many healthcare systems. But how does a new treatment move from scientific evidence into routine clinical practice?

In this episode of the Neurocare Academy Podcast, Dr. Trevor Brown is joined by Dr. Mohamed Abdelghani, Consultant Psychiatrist, international TMS educator, former President of the Clinical TMS Society, and founder of one of London's earliest NHS TMS services. Together, they discuss the practical realities of introducing innovative treatments into healthcare systems and the lessons learned from helping establish TMS services within the NHS.

The conversation explores why health economics play a crucial role in driving adoption, why public and clinician awareness still lag behind the evidence, and how expanding access to TMS could help address the growing burden of treatment-resistant depression.

Dr. Abdelghani also shares his perspective on the future of neuromodulation, including accelerated TMS protocols, connectivity-guided treatment approaches, and emerging applications beyond depression.

In this episode:

• The journey of TMS from research to NHS implementation
• Building one of London's first NHS TMS services
• The role of health economics in healthcare innovation
• Challenges surrounding awareness and access to TMS
• Accelerated TMS and the future of treatment delivery
• Connectivity-guided neuromodulation
• Potential future applications in ADHD and other conditions

Key Takeaways

• TMS became NHS-funded in 2016 and continues to expand across the UK.
• Successfully implementing innovation requires clinical, operational, and economic expertise.
• Greater public awareness is essential if more patients are to benefit from evidence-based neuromodulation treatments.

Neurocare Academy features conversations with leading experts at the forefront of neuroscience, neuromodulation, and evidence-based mental healthcare.

Post-traumatic stress disorder remains one of the most difficult mental health conditions to treat, yet advances in neuromodulation are creating new opportunities for patients and clinicians alike.

In this episode of the neurocare Academy Podcast, Dr. Trevor Brown is joined by Dr. Noah Philip, Professor of Psychiatry and Human Behavior at Brown University, to discuss how technologies such as transcranial magnetic stimulation (TMS) are reshaping PTSD treatment and what the future of precision psychiatry may look like.

The conversation explores the growing evidence supporting TMS for PTSD, practical considerations for implementation, evolving insights from brain connectivity research, and the promise of accelerated treatment protocols. Dr. Philip also shares his perspective on one of the field's most exciting frontiers: low-intensity focused ultrasound and its potential to influence deep brain circuits non-invasively.

In this episode:

• The rise of TMS as a treatment for PTSD
• Practical implementation in clinical settings
• Brain network models of PTSD
• Accelerated neuromodulation approaches
• Maintenance treatment and durability
• The future of focused ultrasound
• Precision psychiatry and personalized care

neurocare Academy features conversations with leading experts at the forefront of neuroscience, neuromodulation, and evidence-based mental health care.

Can transcranial magnetic stimulation (TMS) be adapted to better address anxiety symptoms in patients with depression?

In this episode of the neurocare Academy Podcast, Dr. Trevor Brown sits down with Dr. Shan H. Siddiqi, Assistant Professor of Psychiatry at Harvard Medical School, to discuss a groundbreaking randomized clinical trial investigating whether different TMS targets can influence anxiety and depression symptoms differently.

The conversation explores the growing field of precision psychiatry, where treatment selection is increasingly informed by brain circuits and symptom profiles rather than diagnosis alone. Dr. Siddiqi explains how his team's research identified a dorsomedial prefrontal cortex target that may improve anxiety symptoms more effectively in patients experiencing both depression and anxiety, while maintaining comparable antidepressant effects.

Beyond the study results, the discussion examines how these protocols can be implemented in everyday clinical practice, the role of neuronavigation and imaging-guided targeting, and why accumulating evidence from multiple studies is helping shape the future of personalized brain stimulation.

In this episode:

• Why anxiety and depression may involve distinct brain circuits.
• Findings from a randomized head-to-head TMS trial.
• The potential clinical relevance of the dorsomedial prefrontal cortex target.
• Practical considerations for implementing new TMS targets in routine care.
• The future of biomarkers, patient stratification, and personalized neuromodulation.

Related publication:
Read the study in Molecular Psychiatry

The neurocare Academy Podcast features conversations with leading researchers, clinicians, and innovators exploring the latest developments in neuroscience, neuromodulation, and evidence-based mental health care.